Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy

Advancements in chimeric antigen receptor engineered T-cell (CAR-T) therapy have revolutionized treatment for several cancer types over the past decade. Despite this success, obstacles including the high price tag, manufacturing complexity, and treatment-associated toxicities have limited the broad application of this therapy. Chimeric antigen receptor engineered natural killer cell (CAR-NK) therapy offers a potential opportunity for a simpler and more affordable “off-the-shelf” treatment, likely with fewer toxicities. Unlike CAR-T, CAR-NK therapies are still in early development, with few clinical trials yet reported. Given the challenges experienced through the development of CAR-T therapies, this review explores what lessons we can apply to build better CAR-NK therapies. In particular, we explore the importance of optimizing the immunochemical properties of the CAR construct, understanding factors leading to cell product persistence, enhancing trafficking of transferred cells to the tumor, ensuring the metabolic fitness of the transferred product, and strategies to avoid tumor escape through antigen loss. We also review trogocytosis, an important emerging challenge that likely equally applies to CAR-T and CAR-NK cells. Finally, we discuss how these limitations are already being addressed in CAR-NK therapies, and what future directions may be possible.

[1]  S. McComb,et al.  Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles. , 2023, Molecular therapy. Methods & clinical development.

[2]  M. Liedtke,et al.  Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results , 2023, Nature Medicine.

[3]  Scott D. Brown,et al.  CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies , 2022, Frontiers in Immunology.

[4]  U. Höpken,et al.  Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma , 2022, Nature Communications.

[5]  Hong Wang,et al.  A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML , 2022, Blood.

[6]  B. George,et al.  Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India , 2022, Bone Marrow Transplantation.

[7]  J. Spanholtz,et al.  Natural killer cells in clinical development as non-engineered, engineered, and combination therapies , 2022, Journal of Hematology & Oncology.

[8]  M. Caligiuri,et al.  The emerging field of oncolytic virus-based cancer immunotherapy. , 2022, Trends in cancer.

[9]  D. Gfeller,et al.  Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization , 2022, Journal for immunotherapy of cancer.

[10]  P. Sidaway Allogeneic CAR T cells show promise , 2022, Nature Reviews Clinical Oncology.

[11]  Rui Mao,et al.  The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: Moderate is better , 2022, Frontiers in Immunology.

[12]  Tamara J Laskowski,et al.  KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape , 2022, Nature Medicine.

[13]  A. Weljie,et al.  ATF3 and CH25H regulate effector trogocytosis and anti-tumor activities of endogenous and immunotherapeutic cytotoxic T lymphocytes. , 2022, Cell metabolism.

[14]  Qin Dang,et al.  Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy , 2022, Theranostics.

[15]  J. Martínez-López,et al.  Overcoming tumor resistance mechanisms in CAR-NK cell therapy , 2022, Frontiers in Immunology.

[16]  Bahram Valamehr,et al.  Dual-antigen targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia. , 2022, Blood.

[17]  Youcai Deng,et al.  Natural killer cell homing and trafficking in tissues and tumors: from biology to application , 2022, Signal Transduction and Targeted Therapy.

[18]  R. Kiessling,et al.  Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality , 2022, Oncoimmunology.

[19]  J. Rasko,et al.  Locoregional Delivery of CAR-T Cells in the Clinic. , 2022, Pharmacological research.

[20]  Xin Ma,et al.  CD58 loss in tumor cells confers functional impairment of CAR T cells , 2022, Blood advances.

[21]  A. Biondi,et al.  The Past, Present, and Future of Non-Viral CAR T Cells , 2022, Frontiers in Immunology.

[22]  N. Shah,et al.  Bispecific CAR T-cells for B-cell Malignancies , 2022, Expert opinion on biological therapy.

[23]  Byung Chan Lee,et al.  A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma , 2022, Frontiers in Immunology.

[24]  T. Luetkens,et al.  Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion , 2022, Leukemia.

[25]  Z. Jiang,et al.  CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma. , 2022, Cytotherapy.

[26]  Y. Si,et al.  A Novel Sushi-IL15-PD1 CAR-NK92 Cell Line With Enhanced and PD-L1 Targeted Cytotoxicity Against Pancreatic Cancer Cells , 2022, Frontiers in Oncology.

[27]  C. Ramos,et al.  Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion , 2022, Nature Reviews Clinical Oncology.

[28]  Z. Berneman,et al.  Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells , 2022, Journal of Translational Medicine.

[29]  J. Lomakin,et al.  Feeder-Cell-Free and Serum-Free Expansion of Natural Killer Cells Using Cloudz Microspheres, G-Rex6M, and Human Platelet Lysate , 2022, Frontiers in Immunology.

[30]  B. George,et al.  Distributive Manufacturing of CD19 CAR-T Cells Using Clinimacs Prodigy: Real-World Experience and Cost Analysis in India , 2022, Transplantation and Cellular Therapy.

[31]  Leila A. Mashouf,et al.  CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future , 2022, Frontiers in Immunology.

[32]  Soumya Kundu,et al.  Feeder Cells at the Interface of Natural Killer Cell Activation, Expansion and Gene Editing , 2022, Frontiers in Immunology.

[33]  S. McColl,et al.  Harnessing the chemokine system to home CAR-T cells into solid tumors , 2022, Cell reports. Medicine.

[34]  A. McLellan,et al.  Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours , 2022, Cancers.

[35]  Quanjun Yang,et al.  D2HGDH-mediated D2HG catabolism enhances the anti-tumor activities of CAR-T cells in an immunosuppressive microenvironment , 2022, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  Quanyin Hu,et al.  Scattered seeding of CAR T cells in solid tumors augments anticancer efficacy , 2021, National science review.

[37]  T. Mutis,et al.  Tumour Escape from CAR-T Cells , 2022, The EBMT/EHA CAR-T Cell Handbook.

[38]  P. Neeson,et al.  CAR-T Plus Radiotherapy: A Promising Combination for Immunosuppressive Tumors , 2022, Frontiers in Immunology.

[39]  E. Verhoeyen,et al.  Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies , 2021, Cancers.

[40]  P. Corbeau,et al.  NK Cells Acquire CCR5 and CXCR4 by Trogocytosis in People Living with HIV-1 , 2021, bioRxiv.

[41]  Dariusz M Plewczynski,et al.  PRDX-1 Supports the Survival and Antitumor Activity of Primary and CAR-Modified NK Cells under Oxidative Stress , 2021, Cancer Immunology Research.

[42]  S. Jagannath,et al.  Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma , 2021, Blood.

[43]  Sagar M. Utturkar,et al.  Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells , 2021, Proceedings of the National Academy of Sciences.

[44]  A. Schambach,et al.  Generation of an NFκB-Driven Alpharetroviral “All-in-One” Vector Construct as a Potent Tool for CAR NK Cell Therapy , 2021, Frontiers in Immunology.

[45]  Shu Wang,et al.  piggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells , 2021, Molecular therapy. Methods & clinical development.

[46]  T. Guo,et al.  A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma , 2021, Journal of Hematology & Oncology.

[47]  L. Muffly,et al.  Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia , 2021, Blood advances.

[48]  Michael A. Koldobskiy,et al.  Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities , 2021, Journal for ImmunoTherapy of Cancer.

[49]  A. Esmaeilzadeh,et al.  Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects , 2021, Stem Cell Reviews and Reports.

[50]  Shu Wang,et al.  CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model , 2021, Cancer Gene Therapy.

[51]  R. Deberardinis,et al.  Clinically-relevant T cell expansion protocols activate distinct cellular metabolic programs and phenotypes , 2021, bioRxiv.

[52]  Rebecca Borgert Improving outcomes and mitigating costs associated with CAR T-cell therapy. , 2021, The American journal of managed care.

[53]  M. Caligiuri,et al.  Hijacking TYRO3 from Tumor Cells via Trogocytosis Enhances NK-cell Effector Functions and Proliferation , 2021, Cancer Immunology Research.

[54]  Yumin Li,et al.  Gene-Edited Interleukin CAR-T Cells Therapy in the Treatment of Malignancies: Present and Future , 2021, Frontiers in Immunology.

[55]  K. Davis,et al.  CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial , 2021, Nature Medicine.

[56]  S. Luanpitpong,et al.  Selective Cytotoxicity of Single and Dual Anti-CD19 and Anti-CD138 Chimeric Antigen Receptor-Natural Killer Cells against Hematologic Malignancies , 2021, Journal of immunology research.

[57]  A. Schambach,et al.  Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123 , 2021, Viruses.

[58]  Xiaoming Feng,et al.  Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL , 2021, Frontiers in Oncology.

[59]  D. Finlay,et al.  Optimising NK cell metabolism to increase the efficacy of cancer immunotherapy , 2021, Stem Cell Research & Therapy.

[60]  J. Reed,et al.  Lymphocytes and Trogocytosis-Mediated Signaling , 2021, Cells.

[61]  K. Sanber,et al.  Graft‐versus‐host disease risk after chimeric antigen receptor T‐cell therapy: the diametric opposition of T cells , 2021, British journal of haematology.

[62]  Yumin Li,et al.  Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors , 2021, Frontiers in Immunology.

[63]  C. Mason,et al.  Investigation of product derived lymphoma following infusion of piggyBac modified CD19 chimeric antigen receptor T-cells. , 2021, Blood.

[64]  S. Woodhouse,et al.  Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells , 2021, Journal for ImmunoTherapy of Cancer.

[65]  H. Karasuyama,et al.  The Role of Trogocytosis in the Modulation of Immune Cell Functions , 2021, Cells.

[66]  Jianxiang Wang,et al.  Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy , 2021, Journal of Hematology & Oncology.

[67]  O. Ottmann,et al.  Tinkering under the Hood: Metabolic Optimisation of CAR-T Cell Therapy , 2021, Antibodies.

[68]  Arjun Gupta,et al.  CAR-T cell persistence in the treatment of leukemia and lymphoma , 2021, Leukemia & lymphoma.

[69]  Dacheng Ma,et al.  Sense-and-Respond Payload Delivery Using a Novel Antigen-Inducible Promoter Improves Suboptimal CAR-T Activation , 2021, bioRxiv.

[70]  J. Marshall,et al.  Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer , 2021, Cancers.

[71]  Rosalie M Sterner,et al.  CAR-T cell therapy: current limitations and potential strategies , 2021, Blood Cancer Journal.

[72]  R. Gottardi,et al.  Engineering Metabolism of Chimeric Antigen Receptor (CAR) Cells for Developing Efficient Immunotherapies , 2021, Cancers.

[73]  R. Başar,et al.  GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells , 2021, Frontiers in Immunology.

[74]  P. Mangeot,et al.  Baboon Envelope Pseudotyped “Nanoblades” Carrying Cas9/gRNA Complexes Allow Efficient Genome Editing in Human T, B, and CD34+ Cells and Knock-in of AAV6-Encoded Donor DNA in CD34+ Cells , 2021, Frontiers in Genome Editing.

[75]  B. Becher,et al.  Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma , 2021, Nature Communications.

[76]  D. Wainwright,et al.  NK cell-based cancer immunotherapy: from basic biology to clinical development , 2021, Journal of Hematology & Oncology.

[77]  S. Gottschalk,et al.  Allogeneic CAR Cell Therapy—More Than a Pipe Dream , 2021, Frontiers in Immunology.

[78]  R. Shivakumar,et al.  CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide , 2020, Haematologica.

[79]  Depei Wu,et al.  Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma , 2020, Cancer medicine.

[80]  Muhammad Yasir Anwar,et al.  A systematic review and meta-analysis of CD-19-specific CAR-T cell therapy in relapsed/refractory acute lymphoblastic leukaemia in paediatrics and young adults: Safety and efficacy outcomes , 2020 .

[81]  Z. Berneman,et al.  Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma , 2020, Journal of Hematology & Oncology.

[82]  Shannon K. Boi,et al.  MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects , 2020, Nature Immunology.

[83]  K. Sachs,et al.  High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment , 2020, bioRxiv.

[84]  S. Rosenberg,et al.  Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  Michael R. Green,et al.  Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas , 2020, Nature Medicine.

[86]  Jianzhu Chen,et al.  CAR-NK cells: A promising cellular immunotherapy for cancer , 2020, EBioMedicine.

[87]  F. Gao,et al.  CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. , 2020, Blood.

[88]  A. Sharpe,et al.  When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer , 2020, bioRxiv.

[89]  Kole T. Roybal,et al.  CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma. , 2020, Blood advances.

[90]  S. Badeti,et al.  Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways , 2020, Molecular therapy. Methods & clinical development.

[91]  W. Dunn,et al.  Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity. , 2020, Blood.

[92]  S. Eichmüller,et al.  Cost of decentralized CAR T‐cell production in an academic nonprofit setting , 2020, International journal of cancer.

[93]  N. Nickel,et al.  GMP-compliant, automated process for generation of CAR NK cells in a closed system for clinical use , 2020 .

[94]  Zhiqiang Wu,et al.  Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia , 2020, Journal of Hematology & Oncology.

[95]  M. Vitale,et al.  Mechanisms of Resistance to NK Cell Immunotherapy , 2020, Cancers.

[96]  P. Thall,et al.  Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. , 2020, The New England journal of medicine.

[97]  S. Thorne,et al.  CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency , 2020, Journal for ImmunoTherapy of Cancer.

[98]  P. Duchateau,et al.  ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges , 2020, Nature Reviews Drug Discovery.

[99]  Shu Wang,et al.  CXCR1 Expression to Improve Anti-Cancer Efficacy of Intravenously Injected CAR-NK Cells in Mice with Peritoneal Xenografts , 2019, Molecular therapy oncolytics.

[100]  E. Haddad,et al.  Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector , 2019, Front. Immunol..

[101]  M. Becker-Hapak,et al.  Cytokine-Induced Memory-like (ML) NK Cells Persist for > 2 Months Following Adoptive Transfer into Leukemia Patients with a MHC-Compatible Hematopoietic Cell Transplant (HCT) , 2019, Blood.

[102]  Xiongfong Chen,et al.  Mesothelin Enhances Tumor Vascularity in Newly Forming Pancreatic Peritoneal Metastases , 2019, Molecular Cancer Research.

[103]  A. Plückthun,et al.  Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors , 2019, Clinical Cancer Research.

[104]  C. Mackall,et al.  Clinical lessons learned from the first leg of the CAR T cell journey , 2019, Nature Medicine.

[105]  G. Lucchini,et al.  Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR , 2019, Nature Medicine.

[106]  M. Raffeld,et al.  Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. , 2019, Blood advances.

[107]  Marcela V Maus,et al.  CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity , 2019, Nature Biotechnology.

[108]  C. Gardiner NK Cell Metabolism and the Potential Offered for Cancer Immunotherapy , 2019, Immunometabolism.

[109]  A. Schambach,et al.  Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering , 2019, Human gene therapy methods.

[110]  Yan Sun,et al.  Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[111]  Q. Rao,et al.  2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies , 2019, Journal of Hematology & Oncology.

[112]  P. George,et al.  Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations , 2019, Clinical & translational immunology.

[113]  E. Pearce,et al.  Metabolic interventions in the immune response to cancer , 2019, Nature Reviews Immunology.

[114]  H. Atkins,et al.  Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. , 2019, Transfusion medicine reviews.

[115]  R. Cabeza,et al.  Present and Future , 2008 .

[116]  M. Sadelain,et al.  CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape , 2019, Nature.

[117]  C. Pui,et al.  A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia , 2019, Journal of Immunotherapy for Cancer.

[118]  K. Curran,et al.  CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response. , 2019, Cancer cell.

[119]  E. Moon,et al.  CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment , 2019, Front. Immunol..

[120]  I. Flinn,et al.  Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. , 2019, The Lancet. Oncology.

[121]  D. Porter,et al.  Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T cell efficacy. , 2018, Blood.

[122]  K. Takenaka,et al.  Reinforce the antitumor activity of CD8+ T cells via glutamine restriction , 2018, Cancer science.

[123]  C. Mackall,et al.  Tumor Antigen Escape from CAR T-cell Therapy. , 2018, Cancer discovery.

[124]  Hans Bitter,et al.  Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia , 2018, Nature Medicine.

[125]  Katayoun Rezvani,et al.  Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. , 2018, Current opinion in immunology.

[126]  C. June,et al.  Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager , 2018, Cancer Immunology Research.

[127]  Omkar U. Kawalekar,et al.  CAR T cell immunotherapy for human cancer , 2018, Science.

[128]  Bing Wang,et al.  An ‘off-the-shelf’ fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies , 2018, Leukemia.

[129]  J. Orange,et al.  Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity , 2018, Leukemia.

[130]  K. Davis,et al.  Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[131]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[132]  S. Rosenberg,et al.  Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[133]  A. Lundqvist,et al.  Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma , 2017, Journal of Immunotherapy for Cancer.

[134]  W. Zehring,et al.  Potentiation of Natural Killer Cells for Cancer Immunotherapy: A Review of Literature , 2017, Front. Immunol..

[135]  S. Riddell,et al.  Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. , 2017, Blood.

[136]  W. Wels,et al.  A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against Rhabdomyosarcoma , 2017, Front. Immunol..

[137]  M. Maus,et al.  Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies , 2016, Computational and structural biotechnology journal.

[138]  R. Brentjens,et al.  Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. , 2016, Biochemical Society transactions.

[139]  M. Perales,et al.  Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[140]  Brian Keith,et al.  Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. , 2016, Immunity.

[141]  Eva M García-Cuesta,et al.  Transfer of the human NKG2D ligands UL16 binding proteins (ULBP) 1–3 is related to lytic granule release and leads to ligand retransfer and killing of ULBP‐recipient natural killer cells , 2015, Immunology.

[142]  Hinrich Abken,et al.  TRUCKs: the fourth generation of CARs , 2015, Expert opinion on biological therapy.

[143]  H. Harigae,et al.  Fratricide of natural killer cells dressed with tumor-derived NKG2D ligand , 2013, Proceedings of the National Academy of Sciences.

[144]  Elaine Coustan-Smith,et al.  Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. , 2012, Cytotherapy.

[145]  Dean Anthony Lee,et al.  Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. , 2012, Blood.

[146]  L. Erickson,et al.  Regulatory roles of the tumor necrosis factor receptor BCMA. , 2012, Critical reviews in immunology.

[147]  J. Koch,et al.  Mechanisms of Tumor and Viral Immune Escape from Natural Killer Cell-Mediated Surveillance , 2011, Journal of Innate Immunity.

[148]  G. Gahrton,et al.  Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. , 2010, Cytotherapy.

[149]  B. Lindgren,et al.  Allogeneic natural killer cells for refractory lymphoma , 2010, Cancer Immunology, Immunotherapy.

[150]  S. Agaugué,et al.  Uptake of CCR7 and acquisition of migratory properties by human KIR+ NK cells interacting with monocyte-derived DC or EBV cell lines: regulation by KIR/HLA-class I interaction. , 2009, Blood.

[151]  D. Campana,et al.  Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. , 2009, Cancer research.

[152]  Rufina Leung,et al.  The Activating NKG2D Ligand MHC Class I-Related Chain A Transfers from Target Cells to NK Cells in a Manner That Allows Functional Consequences1 , 2007, The Journal of Immunology.

[153]  P. Moreau,et al.  Trogocytosis‐based generation of suppressive NK cells , 2007, The EMBO journal.

[154]  S. Chisholm,et al.  Transfer of NKG2D and MICB at the cytotoxic NK cell immune synapse correlates with a reduction in NK cell cytotoxic function. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[155]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[156]  A. R.,et al.  Review of literature , 1969, American Potato Journal.

[157]  E. N. Nolte-‘t Hoen,et al.  Human and murine inhibitory natural killer cell receptors transfer from natural killer cells to target cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[158]  E. Joly,et al.  What is trogocytosis and what is its purpose? , 2003, Nature Immunology.

[159]  T. Brown Observations by immunofluorescence microscopy and electron microscopy on the cytopathogenicity of Naegleria fowleri in mouse embryo-cell cultures. , 1979, Journal of medical microbiology.